FDA Brief

Warning letters Devices

FDA warning letter to

Invacare Corporation

High riskIssued Nov 18, 2021Posted Nov 30, 2021Center for Devices and Radiological Health

FDA warned Invacare over quality-system failures in complaint handling and reporting for its oxygen concentrators.

What happened

FDA inspected Invacare’s medical device operations from May 25 to June 24, 2021 and found the oxygen concentrators were adulterated (not compliant with FDA’s device manufacturing rules). The inspection found complaints not investigated, inadequate complaint and corrective-action procedures, and 13 malfunctions not reported to FDA in required Medical Device Reports.

What FDA found

  1. Invacare did not investigate complaints about possible device failures when the device was past end of life or component wear, or when a component was alleged to be the cause; about 10% of oxygen concentrator complaints from Feb. 1, 2020 to Apr. 30, 2021 were not investigated.

    21 C.F.R. § 820.198(c)
  2. Its complaint procedure was inadequate because harms such as hypoxia were assigned a severity score that the letter questions, and a unit involved in a hospital oxygen complaint was not requested for return.

    21 C.F.R. § 820.198(a)
  3. Its corrective and preventive action procedure did not require further review of complaints coded as “other” to detect recurring problems.

    21 C.F.R. § 820.100(a)(1)
  4. It did not analyze component failures for supplier monitoring even though about 81% of oxygen concentrator complaints were linked to a component as the underlying cause.

    21 C.F.R. § 820.100(a)(1)
  5. Corrective actions for recall Z-0514-2021 were inadequate; a root cause of “poorly defined specification” was not investigated further and no corrective actions were implemented to prevent recurrence.

    21 C.F.R. § 820.100(a)
  6. It failed to submit 13 Medical Device Reports within 30 calendar days for complaints suggesting oxygen concentrator malfunctions likely to cause or contribute to death or serious injury if they recurred.

    21 C.F.R. § 803.50(a)(2)

What FDA wants

FDA tells Invacare to act promptly and respond in writing within 15 business days with the specific corrections, corrective actions, documentation, and a timetable for any actions not completed.

Who should pay attention

  • home oxygen patients and caregivers
  • durable medical equipment suppliers and home care providers
  • device makers with complaint-handling and reporting duties

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk